Cure & Care
First-in-class peptide drug company
is a biopharmaceutical company developing peptide drugs for cancer, alopecia and wound.
Curebio Therapeutics is engaged in the discovery and development of potential first-in-class medicines based on newly discovered pathway effected by ARSs (Aminoacyl tRNA Synthetases)
- Translating novel biology ARS into first-in-class therapies
- MOA of our pipelines was published at eminent academic journals
Our leadership team has a proven track record of researching and developing breakthrough medicines. We are utilizing our combined expertise to commercialize first-in-class drugs for patients with high unmet need through the application of new biological platform ARS.
- CEO: Seo-Yong Cho, Ph.D
- Dr. Cho has 20 years of technology commercialization with extensive experience in technology licensing from academia to industry. Prior to Curebio, Dr. Cho was responsible for the commercialization of Seoul National University (SNU)’s technologies. The commercialization includes either licensing technologies/patents concerned or starting up a new company by researchers. Before joining SNU, he found his own company, Cerectron, Ltd. producing nano materials for pharmaceutical applications and had been worked as CEO for about 10 years.. He received his Ph.D in Material Science from SNU. He is a certified licensing professional and a board member of Licensing Executive Society of Korea.
- CTO: Minchul Park, Ph.D
- Dr. Park has worked for 10 years in the field of target discovery, assay development and drug candidate optimization in the pharmaceutical industry. He has expertise in molecular and cellular biology from basic to applied. He obtained PhD in pharmacy department from Seoul National University with a thesis focusing on the role and mechanism of secreted glycyl-tRNA synthetase, the origin protein of CBT1424, in cancer microenvironment. Based on secreted glycyl-tRNA synthetase, he has developed anti-cancer peptide, CBT1424 in Curebio Co. Ltd..
- CDO: Kyuhang Lee, Ph.D
- Dr. Lee worked at the LG Life Science Research Center and Hanmi Research Center (Korea), almost 20 years as an efficacy and toxicology researcher. Most of his career consists of development for metabolic disease and anticancer drug. He has been working as a CDO at Curebio Research Center from May, 2019. Dr. Lee’s major at B.S. was veterinary medicine and received his Ph.D in college of Pharmacy from Chung-Ang University (Korea) by SGLT 1/2 dual inhibitor as an anti-diabetes drug.
- Scientific Advisory Board: Prof. Roger Kornberg
- Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006. Collectively, Dr. Kornberg’s research has revolutionized modern genetics, molecular biology and the understanding of pathogenesis of various cancer malignancies. Among Dr. Kornberg’s many awards and prizes was the Alfred P. Sloan, Jr., Prize from the General Motors Cancer Research Foundation, and the Robert J. and Claire Pasarow Foundation Medical Research Award in Cancer Research.
ARSs(Aminoacyl tRNA Synthetases) biology
- ARSs are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. (ARSs ligate amino acids to their corresponding tRNAs.) ARS were originally thought to only play a role in protein synthesis but recent genomic and proteomic advances have unveiled hidden biological functions of ARSs beyond their catalytic roles. ARSs have potential for new therapeutic targets and agents through multiple avenues, including direct targeting of the catalytic sites and developing novel biologics from the secreted ARS protein or their peptides. [Nature reviews drug discovery 18, 629-650, 2019]
Disease associations of ARSs
PNAS 32 : 11043-11049 (2008)
|Biocon’s target factory
Nature Biotechnology. Volume 36 Number 9. September 2018.
|Extracellular activities of aminoacyl-tRNA synthetase: new mediators for cell-cell communication.
Top Curr Chem. 344:145-166.
|Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping.
Nat Rev Cancer. 2011. 11:708-18.
|A tipping point for mistranslation and disease.
Nat Struct Mol Bio. 2009. 15:348-9.
|Aminoacyl-tRNA synthetase and their connections to disease.
Proc Natl Acad Sci USA. 2008. 105:11043-9.
|Associated Disease Research|
|Secreted tryptophanyl-tRNA synthetase as a primary defense system against infection.
Nat Microbiol. 2016. 2:16191.
|ARS-interacting multi-functional protein induces proliferation of human bone marrow-derived mesenchymal stem cells by accumulation of b-catenin via fibroblast growth factor receptor 2-mediated activation of Akt.
Stem Cells Dev. 2013. 22:2630-40.
|Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.
Proc Natl Acad Sci USA. 2012. 109:E640-7.
Intellectual Property Curebio Therapeutics has built intellectual property portfolio covering GRS and AIMP1 peptides
Currently CureBio has three defined development projects, all based on our research on human proteins. Our two drug candidates, NeoPep GT and NeoPep A1H are small peptides. Glycyl-tRNA synthetase (GRS)-derived peptides (NeoPep GT) are a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. ARS-interacting multifunctional protein 1 (AIMP1)-derived peptides (NeoPep A1H) comprise a hair growth peptide derived from the natural anti-aging agent, AIMP1. The profile of each drug candidate is described in short in the following diagram.
CBT1424 is Glycyl-tRNA synthetase (GRS)-derived peptides and a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. These novel agents bind with cadherin 6 (CDH6), highly-expressed in kidney and ovarian cancer, and inhibit the ERK signal pathway. CBT1424 thus offer an innovative approach to kidney, ovarian and liver cancer specific therapeutics by inducing cancer cell death with nanomolar potency and by suppressing tumor growth in appropriate in vivo models. Results from initial studies, published in the Proceedings of the National Academy of Sciences (2012), demonstrated that the GRS peptides bind to RCC specific CDH6 sites and inhibit ERK signaling that is highly activated in RCC and critical for cancer cell survival. CDH6 is expressed specifically in kidney (RCC) cancer cells to which GRS peptide shows an exquisite receptor specificity. Our patent protected GRS-derives peptides therefore offer a novel therapeutic approach to kidney cancer. Non-GLP PK and formulation studies have been conducted and GLP-TOX is in progress.
AIMP1 acts on endothelial and immune cells to control angiogenesis and inflammation. In skin wound regions from mice, tumor necrosis factor-α induced AIMP1 expression and secretion from macrophages recruited to the site. AIMP1 also promoted fibroblast proliferation and collagen productions through its N-terminal domain. CBT2005 is a peptide based on N-terminal domain of AIMP1.
AIMP1 (aminoacyl-tRNA synthetase-interacting multi-functional protein 1) is one of three scaffold proteins of a macromolecular protein complex, consisting of several different tRNA synthetases, in the mammalian cytosol. While serving as a scaffold for the assembly of the enzyme complex, AIMP1 can also leave the complex under diverse stress signals and appears to contribute to the restoration of normal physiology. The diverse activities of AIMP1 can further be deconvoluted into distinct peptides, many of which have therapeutic potential. AIMP1 itself has been shown to be critical to the maintenance of healthy hair follicles in skin-specific AIMP1 KO and TG mouse models. CBT2004 is a linear peptide that stimulates hair growth by activating dermal papilla cells and hair follicle stem cells. Efficacy of CBT2004 was confirmed by human hair follicle organoids and in-vivo patch model of human dermal papilla cells. Additional studies have been conducted with a topical formulation in an established mouse (normal black) hair growth model. CBT2004 showed increased hair growth over a topical minoxidil 3% regimen. GLP TOX of CBT2004 finished and showed no toxicity. An IND application is delayed due to COVID19.
CURE BIO Co., Ltd.
- Room 1201, AceGwanggyoTower2, Yeongtong-gu, Suwon, Gyeonggi, Korea (ZIP 16229)
- T. +82-31-216-8861
- F. +82-31-8014-2819
- E. email@example.com